
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**

Filed by the registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material under § 240.14a-12

GT BIOPHARMA, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No Fee Required
 Fee paid previously with preliminary materials
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

On June 17, 2024, GT Biopharma, Inc. (the "**Company**") issued the following letter to its stockholders holding 100 or more shares of the Company's common stock.



**8000 Marina Boulevard
Suite 100
Brisbane, CA 94005
www.gtbiopharma.com**

***** YOUR VOTE IS IMPORTANT*****

June 17, 2024

Dear GT Biopharma Stockholder:

The Annual Meeting of Stockholders is soon approaching and is scheduled to be held on June 25 2024 at 9:00 AM Pacific Time.

We are sending this reminder notice because according to records from the vote processor your shares are unvoted. **Voting is quick and easy.** We urge you promptly to submit your vote by internet or telephone by using the control number located on the enclosed voting instruction form.

Regardless of the number of shares you own; your vote is very important.

If you have any questions or need assistance voting your shares, please contact our proxy solicitor, Saratoga Proxy Consulting at (888) 368-0379 or (212) 257-1311.

Thank you for your continued support,

GT Biopharma
